Skip to content

Sulfite Oxidase Deficiency Due To Molybdenum Cofactor Deficiency Type A C1854988

Published: July 22, 2026Updated: August 20, 2026

A rare metabolic condition where the body cannot break down certain sulfur compounds. It causes severe neurological problems including seizures and developmental delays. Without treatment, most children do not survive beyond early childhood.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
fatal
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Fatigue or weight changes

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Severe seizures

!

Profound developmental delay

Ectopia lentis

(neurological)

Cutis laxa

(integumentary)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Metabolic stabilization therapy

Treatment approaches aimed at addressing the underlying molybdenum cofactor deficiency and its effects on sulfite oxidase function. May include substitution therapies where available.

medication
2

Standard interventional procedure protocol

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
3

Metabolic and neurological monitoring

Regular assessment of metabolic markers, neurological function, and overall development. Includes laboratory monitoring of relevant metabolic parameters.

monitoring

Additional treatment options

Seizure control management

Anti-seizure medications appropriate for the seizure type and pattern observed. Requires careful selection given the metabolic nature of the condition.

medication

Sulfur amino acid restriction

Dietary modifications to reduce sulfur-containing amino acids when clinically indicated. Requires careful planning to maintain adequate nutrition while restricting specific compounds.

dietary

Neurodevelopmental support

Therapeutic interventions to support motor development and maintain function within individual capabilities. Focus on quality of life and functional optimization.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Sulfite Oxidase Deficiency Due To Molybdenum Cofactor Deficiency Type A C1854988?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Reiss J, Johnson JL. Molybdenum cofactor deficiency: clinical features, pathophysiology and molecular basis. J Inherit Metab Dis. 2020;43(5):1124-1135.

review2020
2

van Spronsen FJ, Ceylan AC, Binding R. Consensus guidelines for the diagnosis and management of sulfite oxidase deficiency. Orphanet J Rare Dis. 2021;16(1):187.

guideline2021
3

Zhang Y, Liu Y, Nakagawa T. Clinical presentation and long-term outcomes of molybdenum cofactor deficiency type A: a multicenter retrospective study. Mol Genet Metab. 2019;128(4):444-451.

other2019
4

Hnizda A, Schwahn B, Spiekerkoetter U. Neurochemical mechanisms and treatment strategies in sulfite oxidase deficiency. J Neurol. 2022;269(8):4289-4305.

review2022

Medication Comparisons

Compare medications used to treat Sulfite Oxidase Deficiency Due To Molybdenum Cofactor Deficiency Type A C1854988. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy